Advertisement
Canada markets open in 3 hours 32 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7313
    +0.0015 (+0.21%)
     

  • CRUDE OIL

    82.68
    -0.13 (-0.16%)
     

  • Bitcoin CAD

    87,442.73
    -3,366.35 (-3.71%)
     

  • CMC Crypto 200

    1,360.92
    -21.65 (-1.57%)
     

  • GOLD FUTURES

    2,338.40
    0.00 (0.00%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,523.75
    -140.75 (-0.80%)
     

  • VOLATILITY

    16.17
    +0.20 (+1.25%)
     

  • FTSE

    8,090.94
    +50.56 (+0.63%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6815
    -0.0004 (-0.06%)
     

How Analysts Rate Regenxbio and Peers in April 2018

Kenneth Smith
Updated
How Analysts Rate Regenxbio and Peers in April 2018

Regenxbio (RGNX) is a clinical-stage biotechnology company focused on developing gene therapy product candidates to address genetic defects. The company’s product candidate RGX-314 is designed for the treatment of wet age-related macular degeneration (or wet AMD), which is a leading cause of total and partial vision loss in the US, Europe, and Japan. The other promising product candidate in Regenxbio’s pipeline is RGX-501 for the treatment of homozygous familial hypercholesterolemia (or HoFH).

Continue reading